1962USRx: Prescription Drug Regulation, Cost, and Access: Current Controversies in Context
2019 - 2020
Harvard Medical School
Honor track (HSPH-HMS214x: Fundamentals of Clinical Trials)
2018 - 2018
Harvard T.H. Chan School of Public Health
Readings in Global Health
2017 - 2018
Friedrich-Alexander-Universität Erlangen-Nürnberg
Master of Health Business Administration - MHBA
2015 - 2017
Friedrich-Schiller-Universität Jena
Dr. rer. nat. (Molecular Medicine)
2013 - 2015
Friedrich-Schiller-Universität Jena
Master of Science (MSc) (Molekularmedizin)
2009 - 2011
Friedrich-Schiller-Universität Jena
Dr. med. (Medizin)
2004 - 2009
Justus-Liebig-Universität Giessen
Grundstudium (Medizin)
2002 - 2004
National University of Ireland, Galway
Doctor of Medicine (MD)
The Hebrew University of Jerusalem
Doctor of Medicine (MD)
Gordon Otto's Skills
Medizinprodukte
Clinical Trials
Nephrology
Klinische Entwicklung
Projektmanagement
Medizin
Leadership Management
Intensive Care
Clinical Research
Biotechnologie
Gordon Otto's Summary
Gordon Otto, based in Munich, BY, DE, is currently a Head of Global Clinical Development at MorphoSys, bringing experience from previous roles at Pieris Pharmaceuticals, Merck KGaA, Darmstadt, Germany and Sandoz. Gordon Otto holds a 2019 - 2020 1962USRx: Prescription Drug Regulation, Cost, and Access: Current Controversies in Context @ Harvard University. With a robust skill set that includes Medizinprodukte, Clinical Trials, Nephrology, Klinische Entwicklung, Projektmanagement and more, Gordon Otto contributes valuable insights to the industry. Gordon Otto has 3 emails on RocketReach.